No Long-Term Safety Data: CDSCO Panel Denies Novo Nordisk's proposal to amend warning statement of Semaglutide Dr. Divya Colin16 March 2025 5:15 PM ISTNew Delhi: Citing that there is no real world long-term safety data for Novo Nordisk's antidiabetic drug Semaglutide tablets (3 mg, 7 mg, 14 mg), the...
Present difference of approved and proposed formulation: CDSCO tells Novo Nordisk's Semaglutide tablet Dr. Divya Colin27 Sept 2024 6:00 PM ISTNew Delhi: In response to the proposal presented by the drug major Novo Nordisk to import and market the antidiabetic drug Semaglutide tablets 1.5 mg,...
Novo Nordisk Gets CDSCO Panel Nod To Study Etavopivat Dr. Divya Colin30 Aug 2024 6:00 PM ISTNew Delhi: The drug major Novo Nordisk has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
CDSCO Panel Approves Novo Nordisk's Protocol Amendment proposal to study Somapacitan Dr. Divya Colin31 July 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has approved the drug major Novo...
Novo Nordisk Gets CDSCO Panel Nod To Import, Market Insulin Icodec to treat diabetes mellitus in adults Dr. Divya Colin2 July 2024 6:00 PM ISTNew Delhi: The drug major Novo Nordisk has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Drug Alert: 50 Drug Samples including Macleods' THYROX75 Fail To Qualify CDSCO Test Dr. Divya Colin30 May 2024 6:00 PM ISTNew Delhi: In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has flagged 50 medicine...
Novo Nordisk Gets CDSCO Panel Nod to Study new medicine NNC0519-0130 Dr. Divya Colin21 April 2024 5:00 PM ISTNew Delhi: The drug major Novo Nordisk has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
CDSCO Panel Approves Novo Nordisk's Protocol Amendment Proposal for CagriSema Study Dr. Divya Colin9 April 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novo...
CDSCO Panel grants Novo Nordisk's Protocol Amendment Proposal For Antidiabetic Drug Semaglutide study Dr. Divya Colin31 March 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Novo...
Submit Post Marketing Safety Data of Indians: CDSCO Panel Tells Novo Nordisk on Semaglutide Warning Statement Dr. Divya Colin5 March 2024 6:00 PM ISTNew Delhi: In response to the proposal presented by the drug major Novo Nordisk for the amendment in the warning statement for the antidiabetic drug...
Submit Safety Data From Phase I CT : CDSCO Panel Tells Novo Nordisk on CagriSema Dr. Divya Colin14 Feb 2024 6:00 PM ISTNew Delhi: Reviewing the Phase II clinical study protocol of CagriSema, a combination medication that includes semaglutide and Cagrilintide, the...
CDSCO Panel Approves Novo Nordisk Protocol Amendment Proposal For CagriSema Dr. Divya Colin17 Jan 2024 5:15 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
